19 terminated. 19 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Terminated 19 |
| Phase 2 | 2 | Terminated 2 |
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TYK2 Inhibition in Paradoxical Psoriasis Deucravacitinib - Psoriasis | Phase 2 / Phase 3 | Terminated | Prof Curdin Conrad | 2 | 2024-06-20 | 2025-04-02 |
| Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis Brodalumab, Ustekinumab, Placebo - Psoriasis | Phase 3 | Terminated | LEO Pharma | 12 | 2022-12-07 | 2025-03-14 |
| Psoriatic Arthritis Study of Izokibep Izokibep, Placebo to izokibep - Psoriatic Arthritis | Phase 2 / Phase 3 | Terminated | ACELYRIN Inc. | 351 | 2022-11-21 | 2025-05-23 |
| Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP Double-blind 200 mg imsidolimab, Placebo, Open-label 200 mg imsidolimab - Generalized Pustular Psoriasis | Phase 3 | Terminated | Vanda Pharmaceuticals | 42 | 2022-04-21 | 2026-03-27 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy Filgotinib, Adalimumab, Placebo to match filgotinib - Psoriatic Arthritis | Phase 3 | Terminated | Gilead Sciences | 67 | 2019-12-03 | 2022-05-16 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy Filgotinib, Placebo to match filgotinib - Psoriatic Arthritis | Phase 3 | Terminated | Gilead Sciences | 106 | 2019-11-13 | 2022-03-18 |
| A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) Mirikizumab - Psoriasis | Phase 3 | Terminated | Eli Lilly and Company | 1936 | 2018-09-03 | 2023-03-21 |
| Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) 5 mg Serlopitant Tablets - Pruritus, Prurigo Nodularis | Phase 3 | Terminated | Vyne Therapeutics Inc. | 558 | 2018-03-15 | 2021-05-20 |
| Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis 210 mg brodalumab, 140 mg brodalumab, Placebo - Psoriatic Arthritis | Phase 3 | Terminated | Bausch Health Americas, Inc. | 478 | 2014-03-01 | 2017-05-19 |
| Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects 210 mg brodalumab, 140 mg brodalumab, ustekinumab - Plaque Psoriasis | Phase 3 | Terminated | Bausch Health Americas, Inc. | 1881 | 2012-09-01 | 2020-01-03 |
| Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα Entecavir, Placebo - Chronic Hepatitis B, Rheumatoid Arthritis | Phase 3 | Terminated | Seoul National University Hospital | 43 | 2012-09-01 | 2017-03-06 |
| P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis 210 mg brodalumab, 140 mg brodalumab, ustekinumab - Moderate to Severe Plaque Psoriasis | Phase 3 | Terminated | Bausch Health Americas, Inc. | 1831 | 2012-08-01 | 2020-01-06 |
| Study to Evaluate Broadlumab vs Placebo and Ustekinumab 210mg Brodalumab, 140mg Brodalumab, Ustekinumab - Psoriasis | Phase 3 | Terminated | MedDerm Associates | 15 | 2012-08-01 | 2016-06-01 |
| Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects 210 mg brodalumab, 140 mg brodalumab, placebo - Psoriasis | Phase 3 | Terminated | Bausch Health Americas, Inc. | 661 | 2012-08-01 | 2020-01-03 |
| A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis CP-690,550 - Psoriasis | Phase 3 | Terminated | Pfizer | 2867 | 2010-09-01 | 2017-06-26 |
| Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis AIN457, Placebo - Non-infectious Uveitis | Phase 3 | Terminated | Novartis Pharmaceuticals | 86 | 2010-08-01 | 2016-01-14 |
| Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315) Infliximab, Infliximab and methotrexate - Psoriasis | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 39 | 2009-10-01 | 2017-04-12 |
| Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563) infliximab - Psoriasis | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 441 | 2006-05-01 | 2017-04-11 |
| Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis Onercept, Placebo - Arthritis, Psoriatic | Phase 3 | Terminated | EMD Serono | 854 | 2004-09-01 | 2013-10-22 |
Arthritis, Psoriatic (6) · Arthritis (1) · Arthritis, Juvenile (1) · Arthritis, Rheumatoid (1) · Bronchiolitis Obliterans Syndrome (1) · Cardiovascular Diseases (1) · Dermatitis (1) · Dermatitis, Atopic (1) · Hepatitis B, Chronic (1) · Lymphoma, Follicular (1) · Myocardial Infarction (1) · Panuveitis (1) · Pruritus (1) · Spondylitis, Ankylosing (1)
Skin Diseases (19) · Skin Diseases, Papulosquamous (19) · Skin and Connective Tissue Diseases (19) · Bone Diseases (6) · Joint Diseases (6) · Musculoskeletal Diseases (6) · Spinal Diseases (6) · Spondylarthritis (6) · Spondylarthropathies (6) · Spondylitis (6) · Arthritis (5) · Immune System Diseases (3) · Pathological Conditions, Signs and Symptoms (3) · Pathologic Processes (2)
brodalumab (6) · Ustekinumab (4) · GLPG0634 (2) · Infliximab (2) · Adalimumab (1) · Double-Blind Method (1) · Methotrexate (1) · Standard of Care (1) · deucravacitinib (1) · entecavir (1) · mirikizumab (1) · recombinant human tumor necrosis factor-binding protein-1 (1) · secukinumab (1) · serlopitant (1) · tofacitinib (1)
Bausch Health Americas, Inc. (4) · Gilead Sciences (2) · Merck Sharp & Dohme LLC (2) · ACELYRIN Inc. (1) · EMD Serono (1) · Eli Lilly and Company (1) · LEO Pharma (1) · MedDerm Associates (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · Prof Curdin Conrad (1) · Seoul National University Hospital (1) · Vanda Pharmaceuticals (1) · Vyne Therapeutics Inc. (1)
United States (14) · Poland (12) · Canada (10) · Spain (10) · Hungary (9) · France (8) · Germany (8) · Australia (7) · Czechia (7) · South Korea (6) · Belgium (5) · Russia (5) · Switzerland (5) · Taiwan (5) · Bulgaria (4)
Curdin Conrad, Professor (1) · Michelle T Pelle, M.D. (1) · Shepard Mpofu, MD, Clinical Development (1)
PMID 32207067, PMID 26422722, PMID 30328108, PMID 30471012, PMID 34606048, PMID 39264399, PMID 20718590, PMID 23621698, PMID 29782642, PMID 32816215, PMID 36777695, PMID 38696034, PMID 39073712, PMID 42047557
2019 (3), 2017 (2), 2009 (1)